-
1
-
-
0038092769
-
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
-
Bumm T., Müller C., Al-Ali H.K., Krohn K., Shepherd P., Schmidt E., et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101 (2003) 1941-1949
-
(2003)
Blood
, vol.101
, pp. 1941-1949
-
-
Bumm, T.1
Müller, C.2
Al-Ali, H.K.3
Krohn, K.4
Shepherd, P.5
Schmidt, E.6
-
2
-
-
34648833625
-
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells
-
Deininger M.W., Cortes J., Paquette R., Park B., Hocchaus A., Baccarani M., et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110 7 (2007) 1509-1519
-
(2007)
Cancer
, vol.110
, Issue.7
, pp. 1509-1519
-
-
Deininger, M.W.1
Cortes, J.2
Paquette, R.3
Park, B.4
Hocchaus, A.5
Baccarani, M.6
-
3
-
-
34347225153
-
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
-
Fabarius A., Haferlach C., Müller M.C., Erben P., Lahaye T., Giehl M., et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 92 (2007) 834-837
-
(2007)
Haematologica
, vol.92
, pp. 834-837
-
-
Fabarius, A.1
Haferlach, C.2
Müller, M.C.3
Erben, P.4
Lahaye, T.5
Giehl, M.6
-
4
-
-
35548939931
-
Philadelphia negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
-
De Melo V.A., Milojkovic D., Khorashad J.S., Marin D., Goldman J.M., Apperley J.F., et al. Philadelphia negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia. Blood 110 (2007) 3086-3087
-
(2007)
Blood
, vol.110
, pp. 3086-3087
-
-
De Melo, V.A.1
Milojkovic, D.2
Khorashad, J.S.3
Marin, D.4
Goldman, J.M.5
Apperley, J.F.6
-
5
-
-
34447576744
-
Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case
-
Zeidan A., Kakati S., Anderson B., Barcos M., and Wetzler M. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case. Cancer Genetics and Cytogenetics 176 (2007) 169-171
-
(2007)
Cancer Genetics and Cytogenetics
, vol.176
, pp. 169-171
-
-
Zeidan, A.1
Kakati, S.2
Anderson, B.3
Barcos, M.4
Wetzler, M.5
-
6
-
-
33750615550
-
Myelodysplastic syndrome and acute leukemia after imatinib mesylate therapy for chronic myeloid leukemia
-
Kovitz C., Kantarjian H.M., Garcia-Manero G., Abruzzo L.V., and Cortes J. Myelodysplastic syndrome and acute leukemia after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108 (2006) 2811-2813
-
(2006)
Blood
, vol.108
, pp. 2811-2813
-
-
Kovitz, C.1
Kantarjian, H.M.2
Garcia-Manero, G.3
Abruzzo, L.V.4
Cortes, J.5
-
7
-
-
34547691666
-
Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia
-
Zaccaria A., Valenti A.M., Donti E., Gozzetti A., Ronconi S., and Spedicato F. Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica 92 (2007) 564-565
-
(2007)
Haematologica
, vol.92
, pp. 564-565
-
-
Zaccaria, A.1
Valenti, A.M.2
Donti, E.3
Gozzetti, A.4
Ronconi, S.5
Spedicato, F.6
-
8
-
-
34447136847
-
Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability
-
Fabarius A., Giehl M., Frank O., Spiess B., Zheng C., Müller M.C., et al. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. British Journal of Haematology 138 (2007) 369-373
-
(2007)
British Journal of Haematology
, vol.138
, pp. 369-373
-
-
Fabarius, A.1
Giehl, M.2
Frank, O.3
Spiess, B.4
Zheng, C.5
Müller, M.C.6
-
9
-
-
0032443366
-
Determination of cell fate by C-Abl activation in response to DNA damage
-
Kharbanda S., Yuan Z.M., Weichselbaum R., and Kufe D. Determination of cell fate by C-Abl activation in response to DNA damage. Oncogene 17 (1998) 3309-3318
-
(1998)
Oncogene
, vol.17
, pp. 3309-3318
-
-
Kharbanda, S.1
Yuan, Z.M.2
Weichselbaum, R.3
Kufe, D.4
-
10
-
-
0032512750
-
Regulation of Rad51 by c-Abl in response to DNA damage
-
Yuan Z.M., Huang Y., Ishiko T., Nakada S., Utsugisawa T., Kharbanda S., et al. Regulation of Rad51 by c-Abl in response to DNA damage. The Journal of Biological Chemistry 273 (1998) 3799-3802
-
(1998)
The Journal of Biological Chemistry
, vol.273
, pp. 3799-3802
-
-
Yuan, Z.M.1
Huang, Y.2
Ishiko, T.3
Nakada, S.4
Utsugisawa, T.5
Kharbanda, S.6
-
11
-
-
70249128370
-
Nilotinib 800 Mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: result of a phase 2 trial of the GIMEMA CML
-
Abstract [0404]
-
Rosti G., Castagnetti F., Palandri F., Breccia M., Levato L., Capucci A., et al. Nilotinib 800 Mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: result of a phase 2 trial of the GIMEMA CML. Working Party Haematologica 93 sp1 (2008) Abstract [0404]
-
(2008)
Working Party Haematologica
, vol.93
, Issue.sp1
-
-
Rosti, G.1
Castagnetti, F.2
Palandri, F.3
Breccia, M.4
Levato, L.5
Capucci, A.6
|